



BETA DRUGS LIMITED

BDL/PKL/SEC/2023

7th December, 2023

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East
Mumbai 400051

Script :-BETA

Sub: Beta Drugs Limited sets a new industry benchmark with a dedicated oral suspension plant of cancer medicines.

Dear Sir/Madam,

Beta Drugs Limited, one of the leading manufacturers of Oncology medicines in India, announces its new setup of a “state-of-the-art” Oral suspension plant of cancer medicines. This plant is meant for the manufacture of suspensions and dry syrups of existing cytotoxic drugs. This month, our company is poised to introduce the NDDS formulation of Megestrol Acetate suspension, marking the first-ever launch of this innovative product in Asia.

This strategic expansion underscores the company's commitment to advancing cancer treatment options and elevating standards within the industry. This new facility boasts world-class infrastructure that adheres to the highest global regulatory standards, equipped with cutting-edge technology. Looking ahead, Beta Drugs Limited envisions this expansion as a stepping stone to make a strong foothold in the Indian market as well as ROW and semi-regulated market.

With a dedicated focus on oncology, the company aims to make substantial contributions to cancer care. The Oral suspension and dry syrup formulations of existing cancer medicines play a crucial role in improving patient compliance and overall treatment outcomes of several pediatric and geriatric cancer patients.

Beta Drugs Limited is among a handful of Indian oncology companies to foresee the importance of R&D and invest heavily in these activities. The research and Development team relentlessly working to develop these NDDS formulations and make existing oncology treatments better through formulation re-innovation. By 2024, the company aims to launch more than 15 NDDS formulations like Liposomes, Nanoparticles, Mircoparticulate systems, suspensions, and dry syrups.

As the company continues to push boundaries and set new standards, this development is poised to reshape the landscape of cancer treatment, bringing hope and improved healthcare to patients worldwide.

**Thanking You
Your's faithfully
For Beta Drugs Ltd.**

**Rahul Batra
Managing Director**

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com